Pharmaceutical services in a Mexican pain relief and palliative care institute

  • Raymundo Escutia Gutierrez
  • Cesar R. Cortez Alvarez
  • Rosa M. Alvarez Alvarez
  • Jorge L. Flores Hernandez
  • Jessica Gutierrez Godinez
  • Jose G. Lopez y Lopez
Keywords: Drug Toxicity, Adverse Drug Reaction Reporting Systems, Mexico

Abstract

Neither the purchase nor the distribution of pharmaceuticals in hospitals and community pharmacies in Mexico is under the care of pharmacists. Some are under control of physicians.

This report presents the results of the implementation of somef pharmaceutical services for the Jalisco Pain Relief, and Palliative Care Institute (Palia Institute), under the direction of the Secretary of Health, Government of Jalisco. The services implemented were drug distribution system, Drug Information Service, Pharmacovigilance Program , and home pharmacotherapy follow-up pilot program for patients with advanced illness, with the ultimate using the appropriate medication.  The drug distribution system included dispensing of opioid pain medications, antidepressants, anticonvulsants, NSAIDs, anxiolytic drugs, steroid drugs, laxatives, and anti-emetics. The frequently used drugs were morphine sulfate (62%), amitriptyline (6.4%), and dextropropoxyphene (5.8%). The Drug Information Service answered 114 consultations, mainly asked by a physician (71%) concerned with adverse drug reactions and contraindications (21%). The pharmacovigilance program identified 146 suspected adverse drug reactions and classified them reasonably as possible (27%), probable (69%), and certain (4%). These were attributed mainly to pregabalin and tramadol.  The home pharmacotherapy follow-up pilot program cared patients with different cancer diagnoses and drug-related problems (DRP), which were identified and classified (according to second Granada Consensus) for pharmaceutical intervention as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%), DRP 5 (24%), or DRP 6 (28%).

This report provides information concerning the accurate use of medication and, above all, an opportunity for Mexican pharmacists to become an part of health teams seeking to resolve drug-related problems.

Downloads

Download data is not yet available.

References

1. El papel del Farmacéutico en el Sistema de Atención de Salud. Tokyo: OMS; 1993.

2. Rivera S, Lopez Orozco M. Design, implementation and assessment of a health education service on the correct use of drugs in a pediatric Mexican hospital. Pharmacy Practice. 2006; 4(1): 9-12.

3. Gutiérrez-Godinez J, Torres-Jácome J, Herrera EV, Albarado A, Ponce D, López-López JG. Seguimiento farmacoterapéutico de antiparasitarios para pacientes pediátricos de Santa Maria Acuexcomac-México. Seguimiento Farmacoterapéutico 2005; 3(3): 150-153.

4. D’Alessio R, Busto U, Girón N. Guía para el Desarrollo de Servicios Farmacéuticos Hospitalarios. Información de Medicamentos. Serie Medicamentos Esenciales y Tecnología OPS/OMS, No. 5.4. October 1997.

5. Rodríguez de Bittner M, Girón Aguilar N. Guía para el Desarrollo de Servicios Farmacéuticos Hospitalarios. Atención farmacéutica al paciente ambulatorio. Serie Medicamentos Esenciales y Tecnología OPS/OMS, No. 5.5. October 1997.

6. Machuca M, Fernández-Llimós F, Faus MJ. Método Dáder: Guía de Seguimiento Farmacoterapéutico. Granada: Universidad de Granada; 1999.

7. NORMA Oficial Mexicana NOM-220-2004, Instalación y operación de la farmacovigilancia. Diario Oficial de la Federación. 15 November 2004.

8. Ley General de Salud de los Estados Unidos Mexicanos. Editorial Sista. México, March 2005.

9. Comité de consenso. Segundo Consenso de Granada Sobre Problemas Relacionados con los Medicamentos. Ars Pharm 2002;43(3-4):175-184.
Published
2007-11-22
Section
Original Research